Predict your next investment

Venture Capital
FINANCIAL | Investment Firms & Funds
coparion.vc

See what CB Insights has to offer

Investments

59

Portfolio Exits

2

Funds

2

About Coparion

Coparion is a venture capital firm helping young technology companies achieve growth.

Coparion Headquarter Location

Charles-de-Gaulle-Platz 1d

Cologne, 50679,

Germany

+49 30 58 58 44 00

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Coparion Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Coparion Rank

Research containing Coparion

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Coparion in 3 CB Insights research briefs, most recently on Sep 20, 2019.

Latest Coparion News

Abalos Therapeutics Raises €32.5M in Series A Extension

Oct 15, 2021

Abalos Therapeutics , a Dusseldorf, Germany-based company harnessing arenaviruses in a differentiated immuno-virotherapy approach to fight cancer, raised €32.5M in Series A extension round. This additional round, which brings the total raised to date to €43m (USD50m), was led by Seventure Partners with participation from Coparion, Ventura BioMed Investors and Hx Bio Ventures as well as existing investors including Boehringer Ingelheim Venture Fund (BIVF), Gründerfonds Ruhr, NRW.BANK and High-Tech Gründerfonds (HTGF). In conjunction with the closing of the Series A financing round extension, Annegret de Baey from Seventure Partners and Sebastian Pünzeler from Coparion will join Abalos’ Supervisory Board. The company intends to use the funds to advance its first product candidate into a Phase 1/2 trial in multiple solid tumors including the expansion cohorts to demonstrate early signs of clinical efficacy as well as fund further pipeline expansion. Led by Dr. Marcus Kostka, CEO, Abalos Therapeutics is advancing a technology platform that harnesses the unique features of the lymphocytic choriomeningitis virus (LCMV), which specifically targets tumor cells. Through its proprietary Fast Evolution Platform, the company is generating variants with optimized anti-tumoral properties to trigger a highly precise and directed immune response that can be utilized for distant metastases and enable long-term disease control. FinSMEs 15/10/2021

Coparion Investments

59 Investments

Coparion has made 59 investments. Their latest investment was in Veertly as part of their Seed VC on October 10, 2021.

CBI Logo

Coparion Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

10/25/2021

Seed VC

Veertly

$2.21M

Yes

1

10/14/2021

Series A - II

Abalos Therapeutics

$35.9M

Yes

3

10/1/2021

Seed VC

emlen

$4.87M

Yes

Montan-Ventures-Saar, Undisclosed Angel Investors, and Undisclosed Investors

3

8/25/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

6/28/2021

Series B - II

Subscribe to see more

$99M

Subscribe to see more

10

Date

10/25/2021

10/14/2021

10/1/2021

8/25/2021

6/28/2021

Round

Seed VC

Series A - II

Seed VC

Series B

Series B - II

Company

Veertly

Abalos Therapeutics

emlen

Subscribe to see more

Subscribe to see more

Amount

$2.21M

$35.9M

$4.87M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Montan-Ventures-Saar, Undisclosed Angel Investors, and Undisclosed Investors

Sources

1

3

3

10

10

Coparion Portfolio Exits

2 Portfolio Exits

Coparion has 2 portfolio exits. Their latest portfolio exit was FastBill on October 07, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

10/7/2021

Acquired

2

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

10/7/2021

00/00/0000

Exit

Acquired

Subscribe to see more

Companies

Subscribe to see more

Valuation

Acquirer

Subscribe to see more

Sources

2

10

Coparion Fund History

2 Fund Histories

Coparion has 2 funds, including Coparion Fund I.

Closing Date

Fund

Fund Type

Status

Amount

Sources

3/21/2018

Coparion Fund I

$338.39M

1

Coparion I

Subscribe to see more

$99M

10

Closing Date

3/21/2018

Fund

Coparion Fund I

Coparion I

Fund Type

Subscribe to see more

Status

Amount

$338.39M

$99M

Sources

1

10

Coparion Team

5 Team Members

Coparion has 5 team members, including current Managing Director, Isabelle Canu.

Name

Work History

Title

Status

Isabelle Canu

Managing Director

Current

Carsten Gellermann

Managing Director

Current

Christian R. Schulte

T-Mobile, Dexia Group, and Publicis Sapient

Managing Director

Current

Christian Stein

Creathor Ventures

Managing Director

Current

David Zimmer

Quadriga Capital, Altira Group, and T-Mobile

Managing Director

Current

Name

Isabelle Canu

Carsten Gellermann

Christian R. Schulte

Christian Stein

David Zimmer

Work History

T-Mobile, Dexia Group, and Publicis Sapient

Creathor Ventures

Quadriga Capital, Altira Group, and T-Mobile

Title

Managing Director

Managing Director

Managing Director

Managing Director

Managing Director

Status

Current

Current

Current

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.